Production / Operations
AYURCANN REPORTS FISCAL YEAR 2025 RECORD SALES OF $55,446,352 IN GROSS REVENUE, FEATURING 21% YEAR-OVER-YEAR INCREASE AND PROVIDES CORPORATE UPDATE
AYUR · Price
Executive Summary
- Ayurcann reported record gross revenue of C$55.45 M, up from C$45.27 M in FY 2024.
- Adjusted EBITDA turned positive at C$0.51 M versus a loss of ‑C$0.35 M in the prior year.
- The company announced a voluntary delisting from the OTCQB, remaining listed on the Canadian Securities Exchange (CSE).
Key Details
- Revenue: C$55,446,352 for FY 2025 vs. C$45,265,235 in FY 2024 (+22%).
- Adjusted EBITDA: C$507,570 for FY 2025 vs. –C$352,492 in FY 2024 (positive swing of C$860 K).
- Product Portfolio: Expanded to 80 SKUs nationwide.
- Distribution Reach: Products available in >75% of licensed retail cannabis stores across Canada; >80% penetration in Ontario with listings in >1,500 stores.
- Operational Highlights: Over 35,500 product listings across seven provinces and territories; continued innovation in vape, concentrate, and flower categories; ongoing investments in supply‑chain efficiency and production scalability.
- Corporate Update: Voluntary delisting from the OTC Markets Group OTCQB Venture Market effective October 30, 2025; CSE ticker “AYUR” remains unchanged.
- Management Comment: CEO Igal Sudman highlighted sustained growth despite price compression, emphasizing market‑share expansion, product diversification, and brand loyalty.
Notable Quotes
“Despite price compression and competitive pressures, our focus on the business‑to‑consumer market has enabled Ayurcann to expand market share, diversify product offerings, and strengthen brand loyalty nationwide.” – Igal Sudman, CEO
Materiality Assessment: Material – Positive (significant financial improvement and strategic corporate action).